天准科技(688003) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was CNY 1,608,741,148.61, a decrease of 2.38% compared to CNY 1,648,022,914.60 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 124,690,602.51, reflecting a significant decline of 42.05% from CNY 215,172,445.39 in 2023[22]. - The basic earnings per share for 2024 decreased to CNY 0.6499, down 42.06% from CNY 1.1217 in 2023[23]. - The company's total assets increased by 12.01% to CNY 3,615,844,123.46 in 2024, compared to CNY 3,228,205,714.64 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY -8,219,890.46, a significant decline from CNY 230,206,737.73 in 2023[22]. - The company's net profit attributable to the parent company was 124.69 million yuan, down 42.05% compared to the previous year[36]. - The gross profit margin for 2024 was 41.17%, remaining stable compared to the previous year[121]. Research and Development - Research and development expenses accounted for 20.79% of operating revenue in 2024, an increase of 1.02 percentage points from 19.77% in 2023[23]. - The company invested CNY 251 million in R&D in 2024, with a total of 724 R&D personnel by the end of the year[41]. - The company has filed 83 new patent applications during the reporting period, including 69 invention patents, and received 38 patent grants[41]. - The company has developed an AI industrial vision detection platform that enhances efficiency in automatic quality inspection and analysis, utilizing a cloud-based training and inference system[71]. - The company has established multiple national and provincial R&D innovation platforms, enhancing its technological capabilities[88]. Corporate Governance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has not reported any special arrangements for corporate governance[8]. - The company held 2 shareholder meetings, 13 board meetings, and 11 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements[173]. - The company has appointed several independent directors to enhance governance, including Xu Dongdong at Borui Biopharmaceuticals since September 2023[184]. - The company’s internal control evaluation report for 2023 was approved, ensuring effective governance[196]. Market and Industry Trends - The global machine vision and visual-guided robot market is projected to reach $18.88 billion in 2024, growing at a compound annual growth rate of 7.2$12.8 billion in 2023, with China's market at $4.4 billion, and expected to grow to$15.9 billion and $5.5 billion in 2024 respectively[62]. Risks and Challenges - The company faces risks related to technology R&D and innovation, with a potential impact on client retention if it fails to meet evolving demands[96]. - The company is exposed to foreign exchange risks, particularly with fluctuations in the RMB/USD exchange rate impacting its financial results[115]. - The company faces a risk of tax incentives not being extended, which could significantly impact operational performance[104]. - Accounts receivable balances are expected to increase from 508.29 million yuan in 2022 to 660.75 million yuan in 2024, posing a risk of bad debts impacting operational performance[102]. Strategic Initiatives - The company aims to enhance its market position and shareholder value through continuous development and innovation in machine vision technology[166]. - The company plans to improve its internal governance structure and decision-making mechanisms to enhance operational efficiency and risk management[170]. - The company is focused on exploring new applications and business opportunities related to general artificial intelligence (AGI) to open up new performance growth points[168]. - The company has implemented an employee stock ownership plan and restricted stock incentive plan for four consecutive years to attract and retain core technical talents, enhancing employee cohesion and core competitiveness[169]. Investment and Financial Health - The company plans to apply for a comprehensive credit limit for 2024 from banks[200]. - The company reported a total investment of ¥19,715,199.32 during the reporting period[147]. - The company has a significant stake in Suzhou Tianzhun Software Co., Ltd., with total assets of ¥6,157.46 million and net profit of ¥5,369.03 million[152]. - The overall financial health of the company remains stable, with a focus on aligning compensation with performance metrics[179].